Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Launched by ASTRAZENECA · Jun 27, 2008
Trial Information
Current as of July 05, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Moderate to severe COPD
- • Smoking history of greater or equal to 10 pack-years
- • Diagnosis of stable moderate to severe COPD as defined by the GOLD Guidelines
- • Postbronchodilator FEV1 from 30% to 79% of predicted values, inclusive
- • Postbronchodilator FEV1/FVC ratio \< 0.70
- Exclusion Criteria:
- • History or presence of asthma, allergic rhinitis, or exercise-induced bronchospasm
- • Hospitalization for an acute COPD exacerbation in the 3 months prior to study entry
- • Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry
- • Eosinophil count of at least 600 cells/mm3
- • Long term oxygen therapy \> 15 hours a day
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Deland, Florida, United States
Tamarac, Florida, United States
North Dartmouth, Massachusetts, United States
Medford, Oregon, United States
Tucson, Arizona, United States
Fullerton, California, United States
Rancho Mirage, California, United States
San Diego, California, United States
Stockton, California, United States
Waterbury, Connecticut, United States
Charlotte, North Carolina, United States
Cincinnati, Ohio, United States
Spartanburg, South Carolina, United States
Lakewood, California, United States
Redlands, California, United States
San Jose, California, United States
Wheat Ridge, Colorado, United States
Hartford, Connecticut, United States
New Britain, Connecticut, United States
Panama City, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Austell, Georgia, United States
Blue Ridge, Georgia, United States
Bowling Green, Kentucky, United States
Hazard, Kentucky, United States
Rochester, Minnesota, United States
Florissant, Missouri, United States
Saint Charles, Missouri, United States
Saint Louis, Missouri, United States
Albany, New York, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
East Providence, Rhode Island, United States
Dallas, Texas, United States
Mckinney, Texas, United States
Midvale, Utah, United States
Richmond, Virginia, United States
Milwaukee, Wisconsin, United States
Patients applied
Trial Officials
Esther Garcia, MD
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials